Ad
related to: acetazolamide dosing for altitude sickness
Search results
Results From The WOW.Com Content Network
Acetazolamide 250 mg twice daily dosing assists in AMS treatment by quickening altitude acclimatization. [37] A study by the Denali Medical Research Project concluded: "In established cases of acute mountain sickness, treatment with acetazolamide relieves symptoms, improves arterial oxygenation, and prevents further impairment of pulmonary gas ...
[9] [10] It has also been used in the treatment of altitude sickness, [11] Ménière's disease, increased intracranial pressure and neuromuscular disorders. [12] Acetazolamide is also used in the critical care setting to stimulate respiratory drive in patients with chronic obstructive pulmonary disease as an off-label indication. [13]
High-altitude pulmonary edema (HAPE) is a life-threatening form of non-cardiogenic pulmonary edema that occurs in otherwise healthy people at altitudes typically above 2,500 meters (8,200 ft). [2] HAPE is a severe presentation of altitude sickness. Cases have also been reported between 1,500–2,500 metres or 4,900–8,200 feet in people who ...
For premium support please call: 800-290-4726 more ways to reach us
Acetazolamide is an inhibitor of carbonic anhydrase.It is used for glaucoma, epilepsy (rarely), idiopathic intracranial hypertension, and altitude sickness. For the reduction of intraocular pressure (IOP), acetazolamide inactivates carbonic anhydrase and interferes with the sodium pump, which decreases aqueous humor formation and thus lowers IOP.
High-altitude cerebral edema (HACE) is a medical condition in which the brain swells with fluid because of the physiological effects of traveling to a high altitude. It generally appears in patients who have acute mountain sickness and involves disorientation, lethargy, and nausea among other symptoms.
Chronic mountain sickness (CMS) is a disease in which the proportion of blood volume that is occupied by red blood cells increases (polycythaemia) and there is an abnormally low level of oxygen in the blood . CMS typically develops after extended time living at high altitude (over 2,500 metres (8,200 ft)).
Very high altitude = 3,500–5,500 metres (11,500–18,000 ft) Extreme altitude = above 5,500 metres (18,000 ft) Travel to each of these altitude regions can lead to medical problems, from the mild symptoms of acute mountain sickness to the potentially fatal high-altitude pulmonary edema and high-altitude cerebral edema .